Cyclerion Therapeutics, Inc.
245 First Street, Riverview II
18th Floor
Cambridge, MA 02142
United States
857 327 8778
https://www.cyclerion.com
版塊: Healthcare
行業: Biotechnology
全職員工: 1
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Regina Graul Ph.D. | President | 372k | 無 | 無 |
| Ms. Rhonda M. Chicko | Chief Financial Officer | 無 | 無 | 1966 |
| Dr. Todd Milne Ph.D. | Senior Vice President of External Innovation | 無 | 無 | 無 |
| Ms. Jessica Rennekamp | Associate Director of Corporate Communications | 無 | 無 | 無 |
截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 無 止，Cyclerion Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
